This lecture explains the pharmaceutical drug development pathway, from early research decisions to regulatory approval with a focus on the following topics:
- How a scientific discovery becomes an approved medicine
- Key stages of pharmaceutical drug development, explained clearly
- What regulators expect and why it matters early
- Common mistakes that slow down or stop promising programs
- Practical guidance for academics and startups moving toward the clinic
?
Registration is required. Sign up
Speakers
Get valuable insights from two highly experienced experts from the Norwegian Medical Product Agency (DMP).
Ingvild Aal?kken
Special advisor DMP
Ingvild is an experienced life science professional with 20+ years experience from the regulatory authorities.
She also has a background from pharmaceutical industry holding positions in Astra and Astra Zeneca.
Ingvild holds an MSc in dentistry from the University of Oslo.
?
Rune Kjeken?
Scientific Director - Advanced Therapies, DMP
Rune has a profound expertise in advanced therapy medicinal products (ATMPs), bridging innovation, clinical development, and regulatory science.
Before joining DMP in 2009, he was for several years the Executive Director, Research & Development at Inovio Biomedical Corporation.
Rune holds a PhD in Molecular Biology from the University of Oslo.
?
SPARK Norway Educational Forum are monthly open meetings organized by UiO:Life Science and SPARK Norway partners.